ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

ClinicalTrials.gov ID: NCT01270971

Public ClinicalTrials.gov record NCT01270971. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Study identification

NCT ID
NCT01270971
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
594 participants

Conditions and interventions

Interventions

  • AN2690 Topical Solution, 5% Drug
  • Solution Vehicle Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2010
Primary completion
Nov 29, 2012
Completion
Jan 7, 2013
Last update posted
Feb 21, 2019

2010 – 2013

United States locations

U.S. sites
27
U.S. states
20
U.S. cities
26
Facility City State ZIP Site status
Investigational Site Tucson Arizona 85741
Investigational Site Hot Springs Arkansas 71913
Investigational Site Burbank California 91505
Investigational Site Los Angeles California 90045
Investigational Site San Francisco California 94115
Investigational Site Denver Colorado 80210
Investigational Site Orange Park Florida 32073
Investigational Site Boise Idaho 83686
Investigational Site Evansville Indiana 47713
Investigational Site Overland Park Kansas 66202
Investigational Site Baltimore Maryland 21214
Investigational Site Fridley Minnesota 55432
Investigational Site Omaha Nebraska 68144
Investigational Site New York New York 10011
Investigational Site New York New York 10155
Investigational Site Rochester New York 14623
Investigational Site Winston-Salem North Carolina 27157
Investigational Site Cincinnati Ohio 45249
Investigational Site South Euclid Ohio 44118
Investigational Site Portland Oregon 97210
Investigational Site Providence Rhode Island 02920
Investigational Site Germantown Tennessee 38138
Investigational Site Austin Texas 78759
Investigational Site College Station Texas 77845
Investigational Site San Antonio Texas 78229
Investigational Site Lynchburg Virginia 24501
Investigational Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01270971, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 21, 2019 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01270971 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →